Abstract
BackgroundTherapeutic bronchoscopy is one of the effective methods in the treatment and management of malignant central airway stenosis (MCAS). However, restenosis after therapeutic bronchoscopy frequently occurs and severe restenosis (SR) can be life-threatening. Therefore, this study aimed at investigating the risk factors for SR after therapeutic bronchoscopy.MethodsThe data of 233 consecutive cases with MCAS who were subjected to therapeutic bronchoscopy between 2015 and 2020 at a tertiary hospital were collected. Patients were divided into SR group and non-SR during 6 months after therapeutic bronchoscopy. Multiple logistic regression analysis was performed to determine the risk factors for SR.ResultsSR during 6 months after therapeutic bronchoscopy occurred in 39.5% (92/233) of patients. The location and the initial degree of MCAS were associated with SR, as assessed by multiple logistic regression analysis (P < 0.05). The risk of SR after therapeutic bronchoscopy in the left main bronchus, right main bronchus, and right intermediate bronchus increased, compared to the risk when of MCAS was located in the trachea (OR (95% CI) of 8.821 (1.850-25.148), 6.583 (1.791–24.189), and 3.350 (0.831–13.511), respectively). In addition, the initial degree of MCAS was positively associated with an increased risk of SR (OR 1.020; 95% CI 1.006–1.035).ConclusionsMCAS located in the left main bronchus, right main bronchus and right intermediate bronchus, as well as the higher initial degree of MCAS were independent risk factors for SR during 6 months after therapeutic bronchoscopy.
Highlights
Malignant central airway stenosis (MCAS) is referred to the stenosis of the central airway including the trachea, left main bronchus (LMB), right main bronchus (RMB), Wang et al BMC Pulm Med (2021) 21:323 in most patients using therapeutic bronchoscopy [2, 6]
The following variables were collected: age, gender, smoking, co-morbidities including hypertension, diabetes, and chronic obstructive pulmonary disease, locations of the lesion, histological type of malignancies, dyspnea index (DI) [8], initial degree of malignant central airway stenosis (MCAS), degree of residual stenosis after therapeutic bronchoscopy, and postbronchoscopy therapies
The present study revealed that the location of the MCAS and its initial degree were associated with severe restenosis (SR) during 6 months after therapeutic bronchoscopy
Summary
Malignant central airway stenosis (MCAS) is referred to the stenosis of the central airway including the trachea, left main bronchus (LMB), right main bronchus (RMB), Wang et al BMC Pulm Med (2021) 21:323 in most patients using therapeutic bronchoscopy [2, 6]. Airway restenosis commonly occurs after therapeutic bronchoscopy with the progress of the tumor. It is important that interventionists know the risk factors and timing of the restenosis in the management and treatment of MCAS. A retrospective study was performed to assess severe restenosis (SR) during 6 months after therapeutic bronchoscopy, to identify the independent risk factors for SR in these patients. Therapeutic bronchoscopy is one of the effective methods in the treatment and management of malignant central airway stenosis (MCAS). Restenosis after therapeutic bronchoscopy frequently occurs and severe restenosis (SR) can be life-threatening. This study aimed at investigating the risk factors for SR after therapeutic bronchoscopy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
